Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.07
FPMI's Cash to Debt is ranked lower than
97% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. FPMI: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
FPMI' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.23 Max: No Debt
Current: 0.07
F-Score: 2
Z-Score: -64.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA (%) -321.44
FPMI's ROA (%) is ranked lower than
96% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. FPMI: -321.44 )
Ranked among companies with meaningful ROA (%) only.
FPMI' s ROA (%) Range Over the Past 10 Years
Min: -1659.13  Med: -309.83 Max: -100
Current: -321.44
-1659.13
-100
ROC (Joel Greenblatt) (%) -25444.44
FPMI's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. FPMI: -25444.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FPMI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19913.04  Med: -4194.26 Max: -186.67
Current: -25444.44
-19913.04
-186.67
EBITDA Growth (3Y)(%) -24.70
FPMI's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. FPMI: -24.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FPMI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.7  Med: 81.45 Max: 460.4
Current: -24.7
-24.7
460.4
EPS Growth (3Y)(%) -12.50
FPMI's EPS Growth (3Y)(%) is ranked lower than
60% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. FPMI: -12.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FPMI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.5  Med: 89.55 Max: 392.6
Current: -12.5
-12.5
392.6
» FPMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with FPMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Current Ratio 0.07
FPMI's Current Ratio is ranked lower than
98% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. FPMI: 0.07 )
Ranked among companies with meaningful Current Ratio only.
FPMI' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.38 Max: 8.72
Current: 0.07
0.01
8.72
Quick Ratio 0.07
FPMI's Quick Ratio is ranked lower than
98% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. FPMI: 0.07 )
Ranked among companies with meaningful Quick Ratio only.
FPMI' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.22 Max: 8.72
Current: 0.07
0.01
8.72

Valuation & Return

vs
industry
vs
history
Price/Graham Number 0.32
FPMI's Price/Graham Number is ranked higher than
94% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. FPMI: 0.32 )
Ranked among companies with meaningful Price/Graham Number only.
FPMI' s Price/Graham Number Range Over the Past 10 Years
Min: 0.36  Med: 0.49 Max: 1.19
Current: 0.32
0.36
1.19
Earnings Yield (Greenblatt) (%) -18.35
FPMI's Earnings Yield (Greenblatt) (%) is ranked lower than
68% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. FPMI: -18.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FPMI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -46.4  Med: 0.00 Max: 0
Current: -18.35
-46.4
0

More Statistics

Revenue(Mil) $0
EPS $ -0.12
Beta0.23
Short Percentage of Float0.00%
52-Week Range $0.14 - 0.50
Shares Outstanding(Mil)33.22

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PVOTF, OTCPK:BSEM, OSTO:KARE, NAS:WINT, OTCPK:EMBT, ASX:IMC » details
FluoroPharma Medical Inc., is a molecular imaging company. It is engaged in the discovery, development and commercialization of proprietary products for the positron emission tomography (PET) market.
» More Articles for FPMI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... May 04 2016
FLUOROPHARMA MEDICAL, INC. Financials Apr 06 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-K, Annual Report Mar 30 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Mar 23 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jan 25 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 14 2016
FluoroPharma Medical Announces Details for Investor Call on January 6th Jan 05 2016
FluoroPharma Medical Announces Details for Investor Call on January 6th Jan 05 2016
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 29 2015
FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer Dec 29 2015
FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer Dec 29 2015
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 24 2015
FLUOROPHARMA MEDICAL, INC. Files SEC form 10-Q, Quarterly Report Nov 16 2015
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Nov 13 2015
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 12 2015
Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the... Oct 23 2015
Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the... Oct 23 2015
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Oct 16 2015
FLUOROPHARMA MEDICAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Oct 08 2015
Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc. Oct 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK